Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Palumbo, J. S.
Right arrow Articles by Bugge, T. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Palumbo, J. S.
Right arrow Articles by Bugge, T. H.
Related Collections
Right arrow Hemostasis, Thrombosis, and Vascular Biology
Right arrow Neoplasia
Right arrow Focus on Hematology
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 15 November 2000, Vol. 96, No. 10, pp. 3302-3309

FOCUS ON HEMATOLOGY

Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells

Joseph S. Palumbo, Keith W. Kombrinck, Angela F. Drew, Timothy S. Grimes, John H. Kiser, Jay L. Degen, and Thomas H. Bugge

From the Divisions of Hematology/Oncology and Developmental Biology, Children's Hospital Research Foundation and University of Cincinnati College of Medicine, Cincinnati, OH.

Detailed studies of tumor cell-associated procoagulants and fibrinolytic factors have implied that local thrombin generation and fibrin deposition and dissolution may be important in tumor growth and dissemination. To directly determine whether fibrin(ogen) or plasmin(ogen) are determinants of the metastatic potential of circulating tumor cells, this study examined the impact of genetic deficits in each of these key hemostatic factors on the hematogenous pulmonary metastasis of 2 established murine tumors, Lewis lung carcinoma and the B16-BL6 melanoma. In both tumor models, fibrinogen deficiency strongly diminished, but did not prevent, the development of lung metastasis. The quantitative reduction in metastasis in fibrinogen-deficient mice was not due to any appreciable difference in tumor stroma formation or tumor growth. Rather, tumor cell fate studies indicated an important role for fibrin(ogen) in sustained adhesion and survival of tumor cells within the lung. The specific thrombin inhibitor, hirudin, further diminished the metastatic potential of circulating tumor cells in fibrinogen-deficient mice, although the inhibitor had no apparent effect on tumor cell proliferation in vitro. The absence of plasminogen and plasmin-mediated fibrinolysis had no significant impact on hematogenous metastasis. The authors concluded that fibrin(ogen) is a critical determinant of the metastatic potential of circulating tumor cells. Furthermore, thrombin appears to facilitate tumor dissemination through at least one fibrin(ogen)-independent mechanism. These findings suggest that therapeutic strategies focusing on multiple distinct hemostatic factors might be beneficial in the containment of tumor metastasis.

© 2000 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Cell Physiol.Home page
C. S. Alves, M. M. Burdick, S. N. Thomas, P. Pawar, and K. Konstantopoulos
The dual role of CD44 as a functional P-selectin ligand and fibrin receptor in colon carcinoma cell adhesion
Am J Physiol Cell Physiol, April 1, 2008; 294(4): C907 - C916.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
S. W. Jackson, T. Hoshi, Y. Wu, X. Sun, K. Enjyoji, E. Cszimadia, C. Sundberg, and S. C. Robson
Disordered Purinergic Signaling Inhibits Pathological Angiogenesis in Cd39/Entpd1-Null Mice
Am. J. Pathol., October 1, 2007; 171(4): 1395 - 1404.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
J.-S. Wang, C.-Y. Chang, S.-E. Chow, Y.-W. Chen, and C.-M. Yang
Exercise modulates platelet-nasopharyngeal carcinoma cell aggregation and subsequent tissue factor and matrix metalloproteinase activities
J Appl Physiol, September 1, 2007; 103(3): 763 - 770.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. S. Palumbo, K. E. Talmage, J. V. Massari, C. M. La Jeunesse, M. J. Flick, K. W. Kombrinck, Z. Hu, K. A. Barney, and J. L. Degen
Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms
Blood, July 1, 2007; 110(1): 133 - 141.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Jain, M. Zuka, J. Liu, S. Russell, J. Dent, J. A. Guerrero, J. Forsyth, B. Maruszak, T. K. Gartner, B. Felding-Habermann, et al.
Platelet glycoprotein Ib{alpha} supports experimental lung metastasis
PNAS, May 22, 2007; 104(21): 9024 - 9028.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
P. Arora, T. K. Ricks, and J. Trejo
Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer
J. Cell Sci., March 15, 2007; 120(6): 921 - 928.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. M. Ghajar, V. Suresh, S. R. Peyton, C. B. Raub, F. L. Meyskens Jr., S. C. George, and A. J. Putnam
A novel three-dimensional model to quantify metastatic melanoma invasion
Mol. Cancer Ther., February 1, 2007; 6(2): 552 - 561.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Matsuo, S. Amano, M. Furuya, K. Namiki, K. Sakurai, M. Nishiyama, T. Sudo, K. Tatsumi, T. Kuriyama, S. Kimura, et al.
Involvement of p38{alpha} Mitogen-activated Protein Kinase in Lung Metastasis of Tumor Cells
J. Biol. Chem., December 1, 2006; 281(48): 36767 - 36775.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Pilch, D. M. Brown, M. Komatsu, T. A. H. Jarvinen, M. Yang, D. Peters, R. M. Hoffman, and E. Ruoslahti
Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds
PNAS, February 21, 2006; 103(8): 2800 - 2804.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. A. Khorana, C. W. Francis, E. Culakova, R. I. Fisher, N. M. Kuderer, and G. H. Lyman
Thromboembolism in Hospitalized Neutropenic Cancer Patients
J. Clin. Oncol., January 20, 2006; 24(3): 484 - 490.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. R. Morris, Y. Ding, T. K. Ricks, A. Gullapalli, B. L. Wolfe, and J. Trejo
Protease-Activated Receptor-2 Is Essential for Factor VIIa and Xa-Induced Signaling, Migration, and Invasion of Breast Cancer Cells
Cancer Res., January 1, 2006; 66(1): 307 - 314.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Sahni, A. A. Khorana, R. B. Baggs, H. Peng, and C. W. Francis
FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis
Blood, January 1, 2006; 107(1): 126 - 131.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
A.-J. Cheng, L.-C. Chen, K.-Y. Chien, Y.-J. Chen, J. T.-C. Chang, H.-M. Wang, C.-T. Liao, and I-H. Chen
Oral Cancer Plasma Tumor Marker Identified with Bead-Based Affinity-Fractionated Proteomic Technology
Clin. Chem., December 1, 2005; 51(12): 2236 - 2244.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
H. Yamashita, J. Kitayama, and H. Nagawa
Hyperfibrinogenemia is a Useful Predictor for Lymphatic Metastasis in Human Gastric Cancer
Jpn. J. Clin. Oncol., October 1, 2005; 35(10): 595 - 600.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. L. Stevenson, S. H. Choi, and A. Varki
Differential Metastasis Inhibition by Clinically Relevant Levels of Heparins--Correlation with Selectin Inhibition, Not Antithrombotic Activity
Clin. Cancer Res., October 1, 2005; 11(19): 7003 - 7011.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Belting, J. Ahamed, and W. Ruf
Signaling of the Tissue Factor Coagulation Pathway in Angiogenesis and Cancer
Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1545 - 1550.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
C. Kockar, O. Kockar, M. Ozturk, M. Dagli, N. Bavbek, and A. Kosar
Global Fibrinolytic Capacity Increased Exponentially in Metastatic Colorectal Cancer
Clinical and Applied Thrombosis/Hemostasis, April 1, 2005; 11(2): 227 - 230.
[Abstract] [PDF]


Home page
BloodHome page
J. S. Palumbo, K. E. Talmage, J. V. Massari, C. M. La Jeunesse, M. J. Flick, K. W. Kombrinck, M. Jirouskova, and J. L. Degen
Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells
Blood, January 1, 2005; 105(1): 178 - 185.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. H. Im, W. Fu, H. Wang, S. K. Bhatia, D. A. Hammer, M. A. Kowalska, and R. J. Muschel
Coagulation Facilitates Tumor Cell Spreading in the Pulmonary Vasculature during Early Metastatic Colony Formation
Cancer Res., December 1, 2004; 64(23): 8613 - 8619.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
A. Dorfleutner, E. Hintermann, T. Tarui, Y. Takada, and W. Ruf
Cross-talk of Integrin {alpha}3{beta}1 and Tissue Factor in Cell Migration
Mol. Biol. Cell, October 1, 2004; 15(10): 4416 - 4425.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
I. Georgakoudi, N. Solban, J. Novak, W. L. Rice, X. Wei, T. Hasan, and C. P. Lin
In Vivo Flow Cytometry: A New Method for Enumerating Circulating Cancer Cells
Cancer Res., August 1, 2004; 64(15): 5044 - 5047.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Camerer, A. A. Qazi, D. N. Duong, I. Cornelissen, R. Advincula, and S. R. Coughlin
Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis
Blood, July 15, 2004; 104(2): 397 - 401.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
X. Shi, B. Gangadharan, L. F. Brass, W. Ruf, and B. M. Mueller
Protease-Activated Receptors (PAR1 and PAR2) Contribute to Tumor Cell Motility and Metastasis
Mol. Cancer Res., July 1, 2004; 2(7): 395 - 402.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. A. Hembrough, J. F. Ruiz, B. M. Swerdlow, G. M. Swartz, H. J. Hammers, L. Zhang, S. M. Plum, M. S. Williams, D. K. Strickland, and V. S. Pribluda
Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity
Blood, May 1, 2004; 103(9): 3374 - 3380.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
M. A. Booden, L. B. Eckert, C. J. Der, and J. Trejo
Persistent Signaling by Dysregulated Thrombin Receptor Trafficking Promotes Breast Carcinoma Cell Invasion
Mol. Cell. Biol., March 1, 2004; 24(5): 1990 - 1999.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. S. Palumbo, K. E. Talmage, H. Liu, C. M. La Jeunesse, D. P. Witte, and J. L. Degen
Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency
Blood, October 15, 2003; 102(8): 2819 - 2827.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
W. H Reinhart
Fibrinogen - marker or mediator of vascular disease?
Vascular Medicine, August 1, 2003; 8(3): 211 - 216.
[Abstract] [PDF]


Home page
Cancer Res.Home page
T. A. Hembrough, G. M. Swartz, A. Papathanassiu, G. P. Vlasuk, W. E. Rote, S. J. Green, and V. S. Pribluda
Tissue Factor/Factor VIIa Inhibitors Block Angiogenesis and Tumor Growth Through a Nonhemostatic Mechanism
Cancer Res., June 1, 2003; 63(11): 2997 - 3000.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
M. Ozturk, N. Sengul, M. Dagli, A. Kosar, and N. Bavbek
Global Fibrinolytic Capacity in Colorectal Cancer: A New Clue to Occult Fibrinolysis
Clinical and Applied Thrombosis/Hemostasis, April 1, 2003; 9(2): 151 - 154.
[Abstract] [PDF]


Home page
Cancer Res.Home page
J. S. Palumbo, J. M. Potter, L. S. Kaplan, K. Talmage, D. G. Jackson, and J. L. Degen
Spontaneous Hematogenous and Lymphatic Metastasis, but not Primary Tumor Growth or Angiogenesis, Is Diminished in Fibrinogen-deficient Mice
Cancer Res., December 1, 2002; 62(23): 6966 - 6972.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Pilch, R. Habermann, and B. Felding-Habermann
Unique Ability of Integrin alpha vbeta 3 to Support Tumor Cell Arrest under Dynamic Flow Conditions
J. Biol. Chem., June 7, 2002; 277(24): 21930 - 21938.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. F. Drew, H. Liu, J. M. Davidson, C. C. Daugherty, and J. L. Degen
Wound-healing defects in mice lacking fibrinogen
Blood, June 15, 2001; 97(12): 3691 - 3698.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020